Compare Stocks

Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. It offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. Its products are used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is based in Xi'an, the People's Republic of China.

Hempacco Co., Inc. engages in the manufacture and sale of smokable hemp and herb products in California. It offers The Real Stuff hemp smokables and flavored hemp rolling papers. The company was incorporated in 2019 and is headquartered in San Diego, California. Hempacco Co., Inc. is a subsidiary of Green Globe International, Inc.

Micromobility.com Inc., an intra-urban transportation company, provides micro-mobility services in Italy and the United States. The company operates through Mobility, Media, and All Other segments. It offers e-scooters, e- bicycles, and e-mopeds. The company provides a sharing economy that allows users to rent electric vehicles directly from the Helbiz mobile application. It is also involved in the acquisition, commercialization, and distribution of contents, such as live sport events; and provision of Helbiz Kitchen, a delivery-only ghost kitchen restaurant that specializes in preparing meals. The company was founded in 2015 and is headquartered in New York, New York.

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.